Pacer Advisors Inc. Acquires 224,865 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Pacer Advisors Inc. raised its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report) by 28.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,023,706 shares of the specialty pharmaceutical company’s stock after buying an additional 224,865 shares during the quarter. Pacer Advisors Inc. owned about 1.63% of Jazz Pharmaceuticals worth $125,916,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in JAZZ. Los Angeles Capital Management LLC grew its stake in shares of Jazz Pharmaceuticals by 558.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after acquiring an additional 273,764 shares in the last quarter. AQR Capital Management LLC raised its stake in shares of Jazz Pharmaceuticals by 40.8% during the 3rd quarter. AQR Capital Management LLC now owns 179,111 shares of the specialty pharmaceutical company’s stock worth $23,184,000 after purchasing an additional 51,871 shares in the last quarter. Thompson Siegel & Walmsley LLC grew its stake in shares of Jazz Pharmaceuticals by 242.8% in the third quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock valued at $35,023,000 after buying an additional 191,648 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Jazz Pharmaceuticals by 3.3% in the 2nd quarter. BlackRock Inc. now owns 6,879,285 shares of the specialty pharmaceutical company’s stock valued at $852,825,000 after purchasing an additional 222,801 shares during the period. Finally, FMR LLC lifted its holdings in Jazz Pharmaceuticals by 8.1% during the 3rd quarter. FMR LLC now owns 1,333,129 shares of the specialty pharmaceutical company’s stock valued at $172,560,000 after purchasing an additional 100,349 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the transaction, the chief accounting officer now directly owns 8,364 shares of the company’s stock, valued at approximately $1,000,668.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CFO Philip L. Johnson purchased 12,000 shares of the business’s stock in a transaction on Friday, March 1st. The shares were acquired at an average price of $119.65 per share, for a total transaction of $1,435,800.00. Following the completion of the acquisition, the chief financial officer now owns 27,932 shares in the company, valued at $3,342,063.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CAO Patricia Carr sold 1,936 shares of the stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total value of $231,623.04. Following the completion of the transaction, the chief accounting officer now owns 8,364 shares in the company, valued at $1,000,668.96. The disclosure for this sale can be found here. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the topic of several research reports. Robert W. Baird started coverage on Jazz Pharmaceuticals in a research report on Wednesday, January 3rd. They issued an “outperform” rating and a $160.00 target price on the stock. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 30th. Needham & Company LLC reissued a “buy” rating and issued a $220.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, March 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $180.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday. Finally, Barclays reduced their target price on Jazz Pharmaceuticals from $235.00 to $230.00 and set an “overweight” rating on the stock in a report on Friday, March 1st. Two equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $195.08.

Check Out Our Latest Stock Analysis on JAZZ

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $120.79 on Tuesday. The firm has a market cap of $7.61 billion, a PE ratio of 19.74, a price-to-earnings-growth ratio of 1.69 and a beta of 0.59. Jazz Pharmaceuticals plc has a 52 week low of $111.25 and a 52 week high of $147.98. The firm’s fifty day moving average is $122.56 and its 200-day moving average is $124.76. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.85 and a current ratio of 2.24.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Free Report) last issued its quarterly earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). Jazz Pharmaceuticals had a net margin of 10.82% and a return on equity of 31.27%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.01 billion. Sell-side analysts predict that Jazz Pharmaceuticals plc will post 16.15 earnings per share for the current year.

Jazz Pharmaceuticals Company Profile

(Free Report)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Recommended Stories

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc (NASDAQ:JAZZFree Report).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.